MAPK
MAPKs are a family of protein kinases involved in a variety of cellular processes, including growth, proliferation, differentiation, and stress responses. The MAPK signaling pathway consists of several tiers, including ERK, JNK, and p38 MAPKs, each playing distinct roles in cellular function. Dysregulation of MAPK signaling is linked to cancer, inflammatory diseases, and metabolic disorders. At CymitQuimica, we offer a wide array of MAPK inhibitors and activators to support your research in cell biology, signal transduction, and disease mechanisms.
Found 892 products of "MAPK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
HPK1-IN-12
CAS:HPK1-IN-12 is a potent inhibitor of HPK1. HPK1-IN-12 has potential for the study of HPK1-related diseases.Formula:C25H24FN5O2Color and Shape:SolidMolecular weight:445.49RAF mutant-IN-1
CAS:RAF mutant-IN-1 is an inhibitor of RAF kinase(IC50 values of 21 nM, 30 nM and 392 nM for C-RAF 340D/Y341D, B-RAFV600E and B-RAFWT, respectively).Formula:C23H18Cl3FN6O2SPurity:98%Color and Shape:SolidMolecular weight:567.85KRAS G12C inhibitor 21
CAS:KRAS G12C inhibitor 21 is a KRAS G12C inhibitor.Formula:C34H30ClN3O4Color and Shape:SolidMolecular weight:580.07MEK-IN-6
CAS:MEK-IN-6 (Example 69), a potent MEK inhibitor, effectively inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells, with an IC50 of 2 nM, making itFormula:C18H20FN3O4SPurity:98%Color and Shape:SolidMolecular weight:393.43Uplarafenib
CAS:Uplarafenib (B-Raf IN 10), a potent BRAF inhibitor (IC50: 50-100 nM), exhibits antitumor effects on solid cancers.Formula:C22H21F3N4O4SPurity:99.98%Color and Shape:SolidMolecular weight:494.49Ref: TM-T63333
1mg54.00€5mg119.00€10mg170.00€25mg359.00€50mg538.00€100mg928.00€1mL*10mM (DMSO)131.00€Ilaprazole sodium hydrate
CAS:Ilaprazole sodium hydrate (IY-81149 sodium hydrate) is a proton pump inhibitor that blocks the transport of HSV particles.Formula:C19H21N4NaO4SPurity:99.2%Color and Shape:SolidMolecular weight:424.45BDP8900
CAS:BDP8900: potent, selective MRCK inhibitor; alters cancer cell shape, reduces mobility and invasion.Formula:C19H23N5SColor and Shape:SolidMolecular weight:353.48CXJ-2
CAS:CXJ-2, a cyclic peptide, binds EDPs, inhibits PI3K/ERK, and reduces hepatic cell growth/migration, offering antifibrotic effects.Formula:C55H87N15O22Purity:98%Color and Shape:SolidMolecular weight:1310.37SOS1-IN-16
CAS:SOS1-IN-16 (Comp 54) serves as a selective SOS1 inhibitor exhibiting an IC50 value of 7.2 nM and demonstrates inhibitory activity against CYP3A4 with an IC50 ofFormula:C30H31F3N4O3Purity:98%Color and Shape:SolidMolecular weight:552.59ERK-IN-2 free base
CAS:ERK-IN-2 free base inhibits ERK2 (IC50: 1.8 nM); potential off-target effects at >10 μM.Formula:C16H17N5O2Color and Shape:SolidMolecular weight:311.34KRAS inhibitor-18
CAS:KRAS inhibitor-18 targets KRAS G12C; IC50: 4.74 μM. Inhibits p-ERK in cancer cells. Promising for pancreatic, colorectal, lung cancer research.Formula:C20H15ClF3N3O2SColor and Shape:SolidMolecular weight:453.87Raf inhibitor 3
CAS:Raf inhibitor 3 (Example 30), a potent inhibitor of both B-Raf and C-Raf, exhibits IC50 values below 15 nM. It is applicable in cancer research studies [1].Formula:C18H19FN8O2SPurity:98%Color and Shape:SolidMolecular weight:430.46KRAS inhibitor-14
CAS:KRAS inhibitor-14 targets G12C (IC50: 0.249 μM) and inhibits p-ERK in cancer cells; promising for pancreatic, colorectal, lung cancers.Formula:C20H15Cl3FN3O2SColor and Shape:SolidMolecular weight:486.77GSK1790627
CAS:GSK1790627, the N-deacetylated metabolite of Trametinib, represents an orally active MEK inhibitor that promotes autophagy and triggers apoptosis [1].Formula:C24H21FIN5O3Color and Shape:SolidMolecular weight:573.36KRAS G12C inhibitor 1R
CAS:KRAS G12C inhibitor 1R can be used in studies about Ras.Formula:C31H36ClFN6O2Color and Shape:SoildMolecular weight:579.11SOS1-IN-13
CAS:SOS1-IN-13 inhibits SOS1 (IC50: 6.5 nM) and pERK (327 nM); potential in cancer research.Formula:C21H22F3N3O2Color and Shape:SolidMolecular weight:405.41KRAS inhibitor-11
KRAS inhibitor-11 is a KRAS inhibitor .Formula:C29H47N9O6Color and Shape:SolidMolecular weight:617.74ERK1/2 inhibitor 7
CAS:ERK1/2 inhibitor 7 is a potent inhibitor of ERK, acting on ERK2 (IC50: 0.94 nM).Formula:C23H22FN7OSColor and Shape:SolidMolecular weight:463.53HPK1 antagonist-1
CAS:HPK1 antagonist-1 (I-792) is an inhibitor targeting HPK1, with potential applications in cancer and immune disease research [1].Formula:C28H29FN6O2Color and Shape:SolidMolecular weight:500.57PF-07284892
CAS:PF-07284892 (ARRY-558) is an orally active allosteric SHP2 inhibitor (IC50 = 21 nM) that reduces pERK expression and may be employed in solid tumour research.Formula:C21H22ClN7SPurity:97.77%Color and Shape:SolidMolecular weight:439.96FGTI-2734
CAS:FGTI-2734, a dual FT/GGT-1 inhibitor (IC50: 250/520 nM), blocks KRAS membrane binding and curbs KRAS-driven pancreatic cancer.Formula:C26H31FN6O2SPurity:99.69%Color and Shape:SolidMolecular weight:510.63Ref: TM-T11282
1mg49.00€5mg113.00€10mg178.00€25mg371.00€50mg557.00€100mg792.00€1mL*10mM (DMSO)129.00€GGTI-297
CAS:GGTI-297 is a potent, cell-permeable, and selective peptidomimetic inhibitor of GGTase I compared to Farnesyl Transferase (FTase).Formula:C26H31N3O3SColor and Shape:SolidMolecular weight:465.61SOS1-IN-14
CAS:SOS1-IN-14 是选择性的、有效的、口服具有活力的 SOS1 抑制剂 (IC50: 3.9 nM)。SOS1-IN-14 能够利用 P-糖蛋白介导的外排机制在肠道内被吸收。SOS1-IN-14 能够用于 KRAS 突变的癌症的研究，且抑瘤效果比 BI-3406 好。Formula:C29H29F3N6O2Color and Shape:SolidMolecular weight:550.57KRAS G12C inhibitor 58
CAS:KRAS G12C inhibitor 58 is utilized in cancer research as an inhibitor of the KRAS G12C mutation [1].Formula:C51H64ClF4N9O8SPurity:98%Color and Shape:SolidMolecular weight:1074.62SB-682330A
CAS:SB-682330A is a Raf kinase inhibitor.Formula:C28H27N3O3Color and Shape:SolidMolecular weight:453.53CMP3a
CAS:CMP3a, a NEK2 inhibitor, hinders GBM in mice and enhances radiotherapy by disrupting EZH2.Formula:C28H27F3N6O2SColor and Shape:SolidMolecular weight:568.61ERK1/2 inhibitor 5
CAS:ERK1/2 inhibitor 5: potent against ERK1/2, may combat cancer and inflammation.Formula:C28H32ClFN6O5Color and Shape:SolidMolecular weight:587.04ZYF0033
CAS:ZYF0033(HPK1-IN-22) is an orally effective inhibitor of HPK1 that inhibits the phosphorylation of MBP proteins and decreases the phosphorylation of SLP76.Formula:C26H30N4O2SPurity:99.70%Color and Shape:SolidMolecular weight:462.61Exarafenib
CAS:Exarafenib (RAF/KIN_2787) is an oral pan-RAF inhibitor with antitumor properties, targeting MAPK signaling in cancer research.Formula:C26H34F3N5O3Purity:98.36% - 99.84%Color and Shape:SolidMolecular weight:521.58Ref: TM-T63644
1mg74.00€5mg160.00€10mg216.00€25mg369.00€50mg540.00€100mg747.00€1mL*10mM (DMSO)To inquireBI-2493
CAS:BI-2493 is a highly selective pan-KRAS inhibitor and structural analog of BI-2865.BI-2493 exhibits antitumor activity and inhibits tumor cell growth.Cost-effective and quality-assured.Formula:C24H27N7OSPurity:97.74% - 99.88%Color and Shape:SoildMolecular weight:461.58Kras4B G12D-IN-1
CAS:Kras4B G12D-IN-1 is an inhibitor of Kras4B G12D with anticancer activity.Kras4B G12D-IN-1 inhibits Kras protein expression.Formula:C16H21ClN2O4SPurity:99.75%Color and Shape:SolidMolecular weight:372.87Ref: TM-T78170
2mg93.00€5mg144.00€10mg230.00€25mg467.00€50mg745.00€100mg1,134.00€500mg2,277.00€1mL*10mM (DMSO)161.00€HG6-64-1
CAS:HG6-64-1 (HMSL 10017-101-1, compound 9 (XI-1)) is a potent and selective B-Raf inhibitor with an IC50 = 0.09 μM in B-raf V600E-transformed Ba/F3 cells.Formula:C32H34F3N5O2Purity:99.89%Color and Shape:SolidMolecular weight:577.64Ref: TM-T15480
1mg69.00€5mg147.00€10mg215.00€25mg371.00€50mg522.00€100mg708.00€1mL*10mM (DMSO)178.00€Pan-RAS-IN-1
CAS:Pan-RAS-IN-1 is an inhibitor of pan-Ras. It disrupts the interaction of Ras proteins and their effectors.Formula:C36H41Cl2F3N6O2Purity:99.77%Color and Shape:SolidMolecular weight:717.65Ref: TM-T16432
1mg75.00€2mg92.00€5mg137.00€10mg205.00€25mg416.00€50mg625.00€100mg888.00€500mg1,783.00€1mL*10mM (DMSO)210.00€MK-8353
CAS:MK-8353 (SCH900353) is a potent, selective and orally available inhibitor of ERK1/2 (IC50s of 23.0 nM and 8.8 nM, respectively)Formula:C37H41N9O3SPurity:96.15% - 97.19%Color and Shape:SolidMolecular weight:691.84Ref: TM-T12069
1mg77.00€2mg92.00€5mg147.00€10mg258.00€25mg557.00€50mg888.00€100mg1,341.00€1mL*10mM (DMSO)217.00€FMK-MEA
CAS:FMK-MEA is a potent and selective p90 Ribosomal S6 Kinase (RSK) inhibitor.Formula:C21H26FN5O2Purity:98%Color and Shape:SolidMolecular weight:399.46KRas G12C inhibitor 2
CAS:KRas G12C inhibitor 2 is a compound that inhibits KRas G12C.Formula:C32H37N7O3Purity:98%Color and Shape:SolidMolecular weight:567.68KRAS inhibitor-31
CAS:KRAS inhibitor-31 (compound 33), a potent agent targeting KRAS, exhibits K D (SPR) values of 0.019 nM for KRas G12D, 0.019 nM for KRas G12C, and 0.096 nM for KRas G12V, illustrating its efficacy across these variants.Formula:C33H30F3N5O4Color and Shape:SolidMolecular weight:617.62RGT-018
CAS:RGT-018 is a potent oral SOS1 inhibitor with antitumor properties. It exerts its anticancer activity by inhibiting KRAS activation, thereby hindering cancer cell proliferation.Formula:C27H24F3N7O2Color and Shape:SolidMolecular weight:535.52KRAS inhibitor-8
CAS:KRAS inhibitor-8 is a potent KRAS G12C inhibitor.Formula:C26H24ClF4N5O3Purity:98%Color and Shape:SolidMolecular weight:565.95p38α-MK2-IN-1
CAS:p38α-MK2-IN-1 (Compound 36) is an inhibitor of the p38α-MK2 complex, with an IC50 of 5 nM. This compound exhibits significant anti-inflammatory properties and has the ability to aid in joint repair.Formula:C27H26F3N5O3Color and Shape:SolidMolecular weight:525.522KRAS inhibitor-27
CAS:KRAS inhibitor-27 (Compound 15h) is a KRAS inhibitor that effectively targets KRAS G12D/G12V mutated cells (AsPC-1 and SW620) and wild-type KRAS cells (HT-29), with IC50 values of 378 nM, 0.6 nM, and 3230 nM, respectively. It reduces ERK phosphorylation, with IC50 values of 0.6 nM and 1 nM in AsPC-1 and SW620 cells, respectively, and decreases DUSP4 expression, thereby inhibiting the MAPK signaling pathway.Formula:C31H28ClF3N6O3SColor and Shape:SolidMolecular weight:657.106pan-Raf/RTK inhibitor 1
CAS:Pan-Raf/RTK inhibitor 1 (compound I-16) is a potent pan-Raf inhibitor with IC50 values of 3.49 nM (BRafV600E), 8.86 nM (ARaf), 5.78 nM (BRafWT), and 1.65 nM (CRaf). It exhibits antiproliferative activity against various cancer cell lines and can be utilized in cancer research.Formula:C29H28F3N7O3Color and Shape:SolidMolecular weight:579.573p38-α MAPK-IN-5
CAS:p38-α MAPK-IN-5: potent p38α inhibitor, IC50s: 0.1 nM (α), 0.2 nM (β), 944 nM (γ), 4100 nM (δ); anti-inflammatory, promising for asthma/COPD research.Formula:C37H49N11O2Color and Shape:SolidMolecular weight:679.86KRAS G12D inhibitor 1
CAS:KRAS G12D inhibitor 1 (example 243) is an inhibitor of KRAS G12D with an IC 50 of 0.8 nM for KRAS G12D-mediated ERK phosphorylation [1].Formula:C33H32F2N6O2Color and Shape:SolidMolecular weight:582.64SOS1-IN-10
SOS1-IN-10 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 13 nM).Formula:C22H19F5N4OColor and Shape:SolidMolecular weight:450.4HPK1-IN-14
CAS:HPK1-IN-14 is a potent inhibitor of HPK1. HPK1-IN-14 has potential for the study of HPK1-related diseases.Formula:C24H23FN6O2Color and Shape:SolidMolecular weight:446.48JAK3-IN-13
JAK3-IN-13: Oral JAK3 inhibitor, selective & potent. Acts on NK1, JNK2, JNK3, Tyk2. Anti-tumor. IC50: JNK3, 8 nM; Tyk2, 365 nM; JNK2, 2039 nM; NK1, 4728 nM.Formula:C25H33ClN6O5Color and Shape:SolidMolecular weight:533.02SOF-436
CAS:SOF-436 is a KRAS inhibitor that can suppress SOS1-mediated KRAS nucleotide exchange (IC50 = 60 μM) and inhibit the interaction between KRAS and the effector protein RAF. SOF-436 is applicable to cancer research.Formula:C15H13F2NO4S2Color and Shape:SolidMolecular weight:373.395Dorrigocin A
CAS:Dorrigocin A, an analog of Migrastatin, inhibits the carboxymethyltransferase involved in Ras processing, reversing the morphology of Ras-transformed NIH/3T3 cells. Dorrigocin A holds potential for research as an anticancer and anti-arthritis agent.Formula:C27H41NO8Color and Shape:SolidMolecular weight:507.616SML-10-70-1
CAS:SML-10-70-1 is a Novel Active Site Inhibitor of Oncogenic K-Ras G12C.Formula:C25H42ClN7O13P2Color and Shape:SolidMolecular weight:746.04KRAS G12D inhibitor 12
KRAS G12D inhibitor 12 targets Ras protein for cancer research. (Patent WO2021108683A1, Compound 134)Formula:C23H21ClFN5O3Color and Shape:SolidMolecular weight:469.9MRTX849 ethoxypropanoic acid
CAS:MRTX849 is a KRAS G12C ligand and PROTAC linker for creating potent LC-2, degrading KRAS G12C with DC50 of 0.25-0.76 μM.Formula:C37H43ClFN7O5Color and Shape:SolidMolecular weight:720.24Sosimerasib
CAS:Sosimerasib is an inhibitor of the kirsten rat sarcoma viral oncogene homolog (KRAS) and exhibits antitumor activity.
Formula:C36H39ClFN7O4Color and Shape:SolidMolecular weight:688.191KRAS G12D inhibitor 3
CAS:KRAS G12D Inhibitor 3, a compound targeting the KRAS G12D mutation, demonstrates potent antitumor efficacy with an inhibitory concentration (IC50) of less thanFormula:C34H31ClF3N5O2Color and Shape:SolidMolecular weight:634.09KRAS G12C inhibitor 50
CAS:KRAS G12C inhibitor 50 is a KRAS G12C inhibitor (IC50: 46.7 nM).Formula:C31H34N8O2Color and Shape:SolidMolecular weight:550.65HPK1-IN-55
CAS:HPK1-IN-55 (compound 19) is a selective and orally active inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 of less than 0.51 nM. It exhibits exceptional kinase selectivity, being over 637 times more selective for HPK1 compared to GCK kinase and over 1022 times compared to LCK. HPK1-IN-55 possesses anti-cancer properties.Formula:C30H34N8O3Color and Shape:SolidMolecular weight:554.643SHR2415
SHR2415: Potent, selective ERK1/2 inhibitor, oral; ERK1 IC50: 2.8 nM, ERK2 IC50: 5.9 nM; effective in Colo205 (IC50: 44.6 nM), for cancer research.Formula:C23H22ClN7O2Color and Shape:SolidMolecular weight:463.92VVD-699
CAS:VVD-699 is a covalent inhibitor of RAS-PI3K. It forms a covalent bond with cysteine at position 242 within the RAS-binding domain of PI3Kp110α, thereby obstructing the ability of RAS to activate PI3K. VVD-699 is capable of inhibiting the growth of tumors with RAS mutations and HER2 overexpression. It is applicable in research related to RAS mutation-associated cancers, such as those involving H358 lung cancer cells, A549 cells, and FaDu cells.Formula:C25H30ClFN2O6S2Color and Shape:SolidMolecular weight:573.097ATX inhibitor 26
CAS:ATX inhibitor 26 is an Autotaxin (ATX) inhibitor with an IC50 of 57 nM in human plasma. It effectively inhibits cell migration and collagen gel contraction. Additionally, ATX inhibitor 26 demonstrates significant antifibrotic activity, reducing collagen deposition in a Bleomycin (BLM)-induced pulmonary fibrosis model.Formula:C18H19Cl2N7O3Color and Shape:SolidMolecular weight:452.30HPK1-IN-30
CAS:HPK1-IN-30 is a potent inhibitor of HPK1. HPK1-IN-30 has potential for cancer disease research.Formula:C25H23FN6Color and Shape:SolidMolecular weight:426.49ERK2 IN-1
CAS:ERK2 IN-1 is a selective ERK2 inhibitor with an IC50 of 7 nM.Formula:C36H34FN7O2SPurity:98%Color and Shape:SolidMolecular weight:647.76AMG-548 dihydrochloride
AMG-548 dihydrochloride, an oral p38α inhibitor (Ki: 0.5 nM), selectively targets p38β, γ, δ, inhibits TNFα (IC50: 3 nM), and suppresses Wnt signaling.Formula:C29H29Cl2N5OColor and Shape:SolidMolecular weight:534.48HPK1-IN-31
HPK1-IN-31 inhibitor with an IC 50 value of 0.8 nM. HPK1-IN-31 has anti-tumour activity and has great potential for immunotherapy .Formula:C30H33N7O3Color and Shape:SolidMolecular weight:539.63HPK1-IN-16
CAS:HPK1-IN-16, a potent HPK1 inhibitor, useful for cancer research and treatment.Formula:C28H27FN4OColor and Shape:SolidMolecular weight:454.54MEK1/2-IN-2
MEK1/2-IN-2 is a potent, ATP-competitive MEK1/2 inhibitor that exhibits equal inhibitory effects on wild-type MEK1/2 and a group of MEK1/2 mutant cells.Formula:C28H22ClFN6OColor and Shape:SolidMolecular weight:512.97HPK1-IN-21
HPK1-IN-21 is a potent, orally active HPK1 kinase inhibitor with a Ki value of 0.8 nM.Formula:C22H25ClFN5O2Color and Shape:SolidMolecular weight:445.92SOS1-IN-6
CAS:SOS1-IN-6 (compound 33-P1) is a potent inhibitor of SOS1, acting on SOS1-G12D (IC50: 14.9 nM) and SOS1-G12V (IC50: 73.3 nM).Formula:C26H28F3N3O2Color and Shape:SolidMolecular weight:471.51Fulzerasib
CAS:Fulzerasib is an orally active KRAS G12C inhibitor that covalently binds to cysteine residue on the protein, thereby inhibiting the growth of KRAS G12C mutantFormula:C32H30ClFN6O4Purity:98.04%Color and Shape:SolidMolecular weight:617.07EBI-907
CAS:EBI-907 is a potent, oral B-RafV600E inhibitor with an IC50 of 4.9 nM, over 10x stronger than Vemurafenib, and effective against key cancer kinases.Formula:C23H21ClF2N4O3SColor and Shape:SolidMolecular weight:506.95MEK4 inhibitor-2
CAS:MEK4 Inhibitor-2, a novel MEK4 inhibitor, demonstrates efficacy against pancreatic adenocarcinoma, exhibiting an IC50 value of 83 nM.Formula:C20H15FN4O3SColor and Shape:SolidMolecular weight:410.42Rho GTPase inhibitor 1
CAS:Rho GTPase inhibitor 1 (compound 7) is a potent inhibitor of Rho GTPase. It exhibits high affinity for Cdc42, Rac1, and RhoA, with dissociation constants (KDs) of 151 μM, 352 μM, and 232 μM, respectively. Additionally, Rho GTPase inhibitor 1 reduces cell migration in glioblastoma cell lines.Formula:C18H16N2OColor and Shape:SolidMolecular weight:276.33KRAS G12C inhibitor 44
KRAS G12C inhibitor 44: potent, oral, anti-cancer; halts cell growth in MIA PaCA-2, H358; effective in vivo. IC50: MIA-0.016μM, H358-0.028μM.Formula:C31H36ClFN6O2Color and Shape:SolidMolecular weight:579.11KRAS inhibitor-41
CAS:KRAS inhibitor-41 is a KRAS inhibitor with an IC50 value of less than 0.01 μM for both KRAS G12D and KRAS G12V mutations. It effectively inhibits RAS mutant cell lines GP2D (KRAS-G12D) and SW620 (KRAS-G12V). KRAS inhibitor-41 is applicable for cancer research.Formula:C30H37FN10OSColor and Shape:SolidMolecular weight:604.745SOS1-IN-9
SOS1-IN-9 is a potent inhibitor of SOS1 that acts on KRAS G12C-SOS1 (IC50: 116.5 nM).Formula:C22H28F3N5OColor and Shape:SolidMolecular weight:435.49HPK1-IN-3
HPK1-IN-3: Selective HPK1 inhibitor, ATP-competitive, IC50=0.25nM; boosts IL-2 in PBMCs, EC50=108nM.Formula:C23H22F4N6O2Color and Shape:SolidMolecular weight:490.45RSK4-IN-1
CAS:RSK4-IN-1 is a compound exhibiting potent inhibition of RSK4, demonstrated by an IC50 value of 9.5 nM.Formula:C19H20F2N4O3Color and Shape:SolidMolecular weight:390.38ERK1/2 inhibitor 6
CAS:ERK1/2 inhibitor 6 - potent cancer/inflammation treatment from WO2021063335A1.Formula:C27H29ClFN7O5Color and Shape:SolidMolecular weight:586.01SHR902275
CAS:SHR902275: potent RAF inhibitor, hits RAS mutations, oral use. cRAF IC50=1.6 nM, bRAFwt IC50=10 nM, bRAFV600E IC50=5.7 nM, hinders cell growth.Formula:C26H23F3N4O4Color and Shape:SolidMolecular weight:512.48AMG-548 hydrochloride
AMG-548 hydrochloride: orally active, p38α inhibitor (Ki=0.5 nM), 1000x less for p38γ/δ, also blocks TNFα (IC50=3 nM) & inhibits casein kinase 1 δ/ε.Formula:C29H28ClN5OColor and Shape:SolidMolecular weight:498.02KRAS inhibitor-13
CAS:KRAS inhibitor-13 blocks KRAS G12C (IC50: 0.883 μM) and p-ERK in some cancer cells; promising for pancreatic, colorectal, lung cancer research.Formula:C25H19ClFN3O2SColor and Shape:SolidMolecular weight:479.95GDC-6036-NH
CAS:GDC-6036-NH is a precursor of compound 17a /b, which is a RAS inhibitor that can be used in cancer research.Formula:C26H30ClF4N7OPurity:99.84%Color and Shape:SolidMolecular weight:568.01INCB159020
CAS:INCB159020 is an orally active inhibitor of KRAS G12D, exhibiting a KRAS G12D SPR value of 2.2 nM. It demonstrates anti-tumor activity.Formula:C37H35ClFN7O2Color and Shape:SolidMolecular weight:664.171MLKL-IN-1
MLKL-IN-1 is a covalent inhibitor of MLKL with a Kd value of 50 μM.Formula:C19H20N2O3Color and Shape:SolidMolecular weight:324.37PF-03715455
CAS:PF-03715455 is a potent p38 MAPK inhibitor, reducing TNFα in blood (IC50=1.7 nM) with selectivity for p38α, and may treat COPD.Formula:C35H34ClN7O3S2Purity:98%Color and Shape:SolidMolecular weight:700.27KRAS G12D inhibitor 28
CAS:KRAS G12D inhibitor 28 (Compound 1) is an inhibitor of KRAS G12D and can be utilized in cancer research.Formula:C35H32Cl2FN5OColor and Shape:SolidMolecular weight:628.57PS-166276
CAS:PS-166276 is a potent p38 inhibitor with low cytotoxicity. It exhibits an IC50 value of 28 nM against p38 kinase and an IC50 of 170 nM in the THP-1 TNFα assay.Formula:C20H30N8OColor and Shape:SolidMolecular weight:398.51Luvometinib
CAS:Luvometinib is an inhibitor of the mitogen-activated protein kinase (MEK) with antitumor activity.Formula:C26H22F2IN5O4SColor and Shape:SolidMolecular weight:665.45ZCL279
CAS:ZCL279 is a small molecule modulator (SMM) that inhibits the interaction between CDC42 and intersectin (ITSN). At lower concentrations (<10 μM), ZCL279 activates Cdc42, a cytoplasmic small GTPase in the Ras superfamily, while at higher concentrations (<10 μM) it significantly inhibits it.Formula:C24H18N2O7S2Color and Shape:SolidMolecular weight:510.539MAP855
CAS:MAP855: potent, selective, oral MEK1/2 inhibitor; IC50=3 nM, pERKEC50=5 nM; effective on wild-type/mutant MEK1/2.Formula:C28H23ClF2N6O3Color and Shape:SolidMolecular weight:564.97G12Si-1
G12Si-1 selectively binds and inhibits K-Ras(G12S) to block oncogenic signaling and nucleotide exchange.Formula:C29H32ClN5O3Color and Shape:SolidMolecular weight:534.05Everafenib
Everafenib: potent BRAF inhibitor, crosses blood-brain barrier, hinders MAPK, effective on V600EBRAF cells, outperforms other drugs in trials.Formula:C20H23ClFN5O2S2Color and Shape:SolidMolecular weight:484.01KRAS inhibitor-21
CAS:KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor (IC50<0.01 μM) that can be used in cancer research.Formula:C33H41N5O3Color and Shape:SolidMolecular weight:555.71KRAS inhibitor-35
CAS:KRAS inhibitor-35 (compound 72) is a KRAS inhibitor with an IC50 of 2 nM, utilized in tumor research.Formula:C38H32F4N6O3SColor and Shape:SolidMolecular weight:728.76KRAS G12C inhibitor 46
CAS:KRAS G12C inhibitor 46 is a potent inhibitor of KRAS G12C.Formula:C32H33F2N7O2Color and Shape:SolidMolecular weight:585.65AZD4625
AZD4625 (Compound 21) is a selective, potent, orally active, covalent and mutagenic mutant GTPaseKRASG12C inhibitor.Formula:C24H21ClF2N4O3Color and Shape:SolidMolecular weight:486.9KRAS inhibitor-36
CAS:KRAS inhibitor-36 (compound Abd2) directly inhibits KRAS Q61H.Formula:C14H13NO4Color and Shape:SolidMolecular weight:259.26MK2-IN-4
CAS:MK2-IN-4 is a MAPKAPK2 (MK2) inhibitor (IC50: 45 nM). MK2-IN-4 can be used in cancer, inflammation and immunology studies.Formula:C25H24N4O2Color and Shape:SolidMolecular weight:412.48KRAS ligand 5
CAS:KRAS ligand 5 acts as the target protein ligand for PROTACK-Ras Degrader-3, which specifically targets and degrades mutated KRAS proteins.Formula:C30H30F2N4O4Color and Shape:SolidMolecular weight:548.58KRAS G12C inhibitor 33
CAS:KRAS G12C inhibitor 33 is a KRAS G12C inhibitor that can be used to study cancer.Formula:C30H33N7O3Color and Shape:SolidMolecular weight:539.63KRASG12C IN-13
CAS:KRASG12C IN-13 (LY3499446), a potent inhibitor of KRAS G12C, shows potential in the study of advanced solid tumors, specifically non-small cell lung cancer and colorectal cancer.Formula:C22H17ClF2N6OSColor and Shape:SolidMolecular weight:486.93
